

# Aspergillosis Drug Development Pipeline Study, H2 2018

<https://marketpublishers.com/r/ADE4A30B038EN.html>

Date: August 2018

Pages: 90

Price: US\$ 1,200.00 (Single User License)

ID: ADE4A30B038EN

## Abstracts

Aspergillosis Drug Development Pipeline Study, H2 2018 is the latest infectious disease publication with comprehensive information of Aspergillosis pipeline products.

### DISEASE OVERVIEW

Aspergillus is a general fungus type that causes different type of infections and allergies on the basis of individual immunity levels. The mould or the fungus is observed both indoors as well as outdoors. Though healthy individuals are typically unaffected people with low immunization or damaged lungs can undergo serious illnesses such as invasive aspergillosis, Allergic Bronchopulmonary Aspergillosis%li%Chronic Pulmonary Aspergillosis and aspergilloma.

Treatment options vary on the basis of infected area and type of mould, with antifungal drugs being mostly administered to the patients.

Though the disease is not life threatening, it is widespread globally and accordingly, 20+ companies are investing their resources in developing therapeutic compounds for treatment of Aspergillus. Both drugs and vaccines can be found in global Aspergillus pipeline.

Companies currently investing in global Aspergillosis pipeline include%li%Acea Biotech Inc, Amplyx Pharmaceuticals Inc, Biosergen AS, Biothera Pharmaceuticals Inc, Cidara Therapeutics Inc, F2G Ltd, iCo Therapeutics Inc., LTN-Pharm Pharmaceutical Company, Lypro Biosciences Inc, Matinas BioPharma Holdings, Merck & Co Inc, Molecular Express Inc, Novabiotics Ltd, Pulmatrix Inc, Pulmocide Ltd, Sealife Pharma GmbH, Vical Inc and Visterra Inc.

## REPORT DESCRIPTION

The Aspergillosis pipeline guide presents complete overview of drugs currently being developed for Aspergillosis. The pipeline review provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials).

Drug development phase, current stage, mechanism of action, route of administration, orphan drug/ fast track/ other designations, drug class are provided for each of the Aspergillosis pipeline candidate.

Research and Development progress along with latest news related to each of the Aspergillosis pipeline candidates is included.

Major companies participating in therapeutic development of Aspergillosis are included in this pipeline report. Company wise pre-clinical and clinical products along with details of drug originator, co-developers/ licensors are provided.

Amid strong interest for cure of Aspergillosis from companies and institutes, the current research work serves as a reliable and comprehensive source of information of global Aspergillosis clinical and pre-clinical products.

The report assists in identifying potential upcoming companies and drugs in Aspergillosis pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

Information in the report is sourced from our proprietary platform, built through extensive primary and secondary research methodology. Data is presented in user friendly and ready to use format.

## SCOPE OF ASPERGILLOSIS PIPELINE REPORT INCLUDES

Panorama of Aspergillosis pipeline markets including statistics on therapeutic drugs and companies involved

Aspergillosis Pipeline candidates across various development phases including both pre-clinical, discovery and clinical stages are covered

Aspergillosis pipeline candidates across various 'Mechanism of Actions' are also presented in the study

Overview of companies participating in Aspergillosis pipeline with short introduction to their businesses and pipeline projects

For each pipeline candidate, drug overview, details of mechanism of Action (MOA), originator, co-developer and licensee are provided.

Research and Development progress and trial details, results wherever available, are also included in the pipeline study

The pipeline study provides information on all ongoing and active projects and also presents the recent news associated with Aspergillosis pipeline therapeutics

## **REASONS TO BUY**

Get clear understanding of the entire Aspergillosis pipeline, with details on active projects

Get in detail information of each product with updated information on each project along with key milestones

Know the list of companies participating in global Aspergillosis pipeline along with progress of each of the company's products and information on associations/collaborations/licensing data

Get trial information for each pipeline product under development

Understand the pipeline structure in terms of mechanism of Action, phase and company

## Contents

### I. KEY FINDINGS

1. Companies Investing in Aspergillosis Pipeline include-
  - Number of Companies with Aspergillosis projects in pre-clinical Development-
  - Number of Companies with Aspergillosis projects in Clinical Development-
  - Aspergillosis Pipeline Companies based in Americas
  - Aspergillosis Pipeline Companies based in Europe
  - Aspergillosis Pipeline Companies based in Asia Pacific
  - Aspergillosis Pipeline Companies based in Rest of the World
2. Pipeline Candidates include-
  - Aspergillosis Pipeline Agents in pre- clinical/Discovery stage of Development
  - Aspergillosis Pipeline Agents in Clinical Development stage
  - Aspergillosis Pipeline Therapeutic Compounds received special status
  - Mechanism of Action of most pipeline Drugs-
  - Small molecules among the Aspergillosis Pipeline agents

### II. INSIGHTS INTO ASPERGILLOSIS PIPELINE

1. Disease Overview
  - Introduction to Aspergillosis
  - Symptoms and Causes of Aspergillosis
  - Treatment or Prevention Options for Aspergillosis
  - Other Details
2. Phase wise Pipeline Compounds
  - Aspergillosis Pipeline- Pre- Clinical/Discovery stage Drugs
  - Aspergillosis Pipeline- Phase 1 stage Drugs
  - Aspergillosis Pipeline- Phase 2 stage Drugs
  - Aspergillosis Pipeline- Phase 3 stage Drugs
  - Aspergillosis Pipeline- Pre-Registration stage Drugs
3. Company wise Aspergillosis Pipeline Compounds
4. Aspergillosis Pipeline by Mechanism of Action

### III. ASPERGILLOSIS PIPELINE COMPOUND DETAILS

Corifungin  
APX001  
APX001A

BSG005  
antifungal vaccines  
CD101 IV  
F901318  
amphotericin B  
novel peptide-based prevention and treatment of invasive aspergillosis  
Mycobactovir  
amphotericin B  
MAT2203  
posaconazole  
VesiVax vaccine  
Novamycin  
PUR1900  
PC1244  
PC945  
SLP0901  
VL-2397  
VIS-FNG

#### Drug Details

##### 1. Snapshot

Name of the Therapeutic Agent  
Originator  
Developing Company  
Co-Developer/License Partner  
Orphan Drug/Fast Track/Designation  
Development Phase

##### 2. Drug Overview

##### 3. Mechanism of Action

##### 4. Current Status

##### 5. Clinical Trial Details

## **IV. ASPERGILLOSIS PIPELINE COMPANY BRIEFS**

Acea Biotech Inc  
Amplix Pharmaceuticals Inc  
Biosergen AS  
Biothera Pharmaceuticals, Inc  
Cidara Therapeutics Inc  
F2G Ltd

iCo Therapeutics Inc.  
LTNpharm LTD  
Lypro Biosciences Inc  
Matinas BioPharma Holdings  
Merck & Co Inc  
Molecular Express Inc  
Novabiotics Ltd  
Pulmatrix Inc  
Pulmocide Ltd  
Sealife PHARMA GMBH  
Vical Inc  
Visterra Inc

## **V. LATEST NEWS AND DEVELOPMENTS IN GLOBAL ASPERGILLOSIS PIPELINE MARKET**

### **VI. APPENDIX**

1. Publisher's Expertise
2. Research Methodology
3. Contact Information

Some of the sections depicted above may be removed or modified on the basis of information availability

## I would like to order

Product name: Aspergillosis Drug Development Pipeline Study, H2 2018

Product link: <https://marketpublishers.com/r/ADE4A30B038EN.html>

Price: US\$ 1,200.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/ADE4A30B038EN.html>